New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETsFirst phase 2 study to evaluate TAT with ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Shares of Perspective Therapeutics (CATX) are down $1.52, or 34%, to $2.97 after the radiopharmaceutical company announced that updated interim ...
Discover ATAI’s pipeline, including promising BPL-003 for TRD, upcoming Phase 3 trials, and a merger with Beckley Psytech.
In September 2024, Sanofi entered an exclusive licensing agreement with Orano Med and RadioMedix to globally commercialize ...
TipRanks on MSN
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
Genmab (GMAB) announced updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan, an investigational folate ...
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate ...
Orano Med’s AlphaMedix met phase 2 endpoints with meaningful responses and manageable safety in PRRT-naïve and PRRT-exposed GEP-NETs; FDA Breakthrough designated.
Orano Med’s AlphaMedix™ hits all efficacy endpoints in a pivotal phase 2 trial for GEP-NETs, showing strong results for both PRRT-naïve and treated patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback